Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

Similar articles for PubMed (Select 23146957)

1.

X chromosome inactivation pattern in BRCA gene mutation carriers.

Manoukian S, Verderio P, Tabano S, Colapietro P, Pizzamiglio S, Grati FR, Calvello M, Peissel B, Burn J, Pensotti V, Allemani C, Sirchia SM, Radice P, Miozzo M.

Eur J Cancer. 2013 Mar;49(5):1136-41. doi: 10.1016/j.ejca.2012.10.013. Epub 2012 Nov 9.

PMID:
23146957
2.

Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.

Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Australian Ovarian Cancer Study Management Group.

J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. doi: 10.1093/jnci/djn345. Epub 2008 Oct 28.

3.

[X chromosome inactivation patterns in patients with Rett syndrome and their mothers and the parental origin of the priority inactive X chromosome].

Jiang SL, Bao XH, Song FY, Pan H, Li MR, Wu XR.

Zhonghua Er Ke Za Zhi. 2006 Sep;44(9):648-52. Chinese.

PMID:
17217653
4.

Heterozygote BRCA1 status and skewed chromosome X inactivation.

Helbling-Leclere A, Lenoir GM, Feunteun J.

Fam Cancer. 2007;6(1):153-7.

PMID:
16944269
5.

Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.

Rutter JL, Wacholder S, Chetrit A, Lubin F, Menczer J, Ebbers S, Tucker MA, Struewing JP, Hartge P.

J Natl Cancer Inst. 2003 Jul 16;95(14):1072-8.

6.

Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Milne RL, Osorio A, Ramón y Cajal T, Baiget M, Lasa A, Diaz-Rubio E, de la Hoya M, Caldés T, Teulé A, Lázaro C, Blanco I, Balmaña J, Sánchez-Ollé G, Vega A, Blanco A, Chirivella I, Esteban Cardeñosa E, Durán M, Velasco E, Martínez de Dueñas E, Tejada MI, Miramar MD, Calvo MT, Guillén-Ponce C, Salazar R, San Román C, Urioste M, Benítez J.

Breast Cancer Res Treat. 2010 Jan;119(1):221-32. doi: 10.1007/s10549-009-0394-1. Epub 2009 Apr 16.

PMID:
19370414
7.

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF.

Am J Hum Genet. 2003 May;72(5):1117-30. Epub 2003 Apr 3. Erratum in: Am J Hum Genet. 2003 Sep;73(3):709.

8.

Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.

Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G.

J Natl Cancer Inst. 2002 Jun 5;94(11):844-51.

9.

Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan.

Liede A, Malik IA, Aziz Z, Rios Pd Pde L, Kwan E, Narod SA.

Am J Hum Genet. 2002 Sep;71(3):595-606. Epub 2002 Aug 13.

10.

Loss of heterozygosity at the BRCA1 and BRCA2 loci detected in ductal lavage fluid from BRCA gene mutation carriers and controls.

Locke I, Kote-Jarai Z, Bancroft E, Bullock S, Jugurnauth S, Osin P, Nerurkar A, Izatt L, Pichert G, Gui GP, Eeles RA.

Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1399-402.

11.

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Narod SA, Dubé MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet JS.

J Natl Cancer Inst. 2002 Dec 4;94(23):1773-9.

12.

Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.

Vicus D, Finch A, Rosen B, Fan I, Bradley L, Cass I, Sun P, Karlan B, McLaughlin J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.

Gynecol Oncol. 2010 Aug 1;118(2):155-9. doi: 10.1016/j.ygyno.2010.03.009. Epub 2010 May 10.

PMID:
20452659
13.

Ductal carcinoma in situ in BRCA mutation carriers.

Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL.

J Clin Oncol. 2007 Feb 20;25(6):642-7. Epub 2007 Jan 8.

14.

Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.

Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A; Institut Curie Breast Cancer Study Group.

Eur J Cancer. 2005 Oct;41(15):2304-11. Epub 2005 Sep 1.

PMID:
16140006
15.

BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.

Antoniou AC, Durocher F, Smith P, Simard J, Easton DF; INHERIT BRCAs program members.

Breast Cancer Res. 2006;8(1):R3. Epub 2005 Dec 12.

16.

The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.

Vencken PM, Kriege M, Hooning M, Menke-Pluymers MB, Heemskerk-Gerritsen BA, van Doorn LC, Collée MM, Jager A, van Montfort C, Burger CW, Seynaeve C.

Cancer. 2013 Mar 1;119(5):955-62. doi: 10.1002/cncr.27839. Epub 2012 Nov 16.

17.

Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Jernström H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, Garber J, Olsson H, Sun P, Narod SA.

J Natl Cancer Inst. 2004 Jul 21;96(14):1094-8.

18.
19.

Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent.

Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, Provencher D, Tonin PN.

BMC Cancer. 2008 Apr 10;8:96. doi: 10.1186/1471-2407-8-96.

20.

Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.

Hughes DJ, Ginolhac SM, Coupier I, Barjhoux L, Gaborieau V, Bressac-de-Paillerets B, Chompret A, Bignon YJ, Uhrhammer N, Lasset C, Giraud S, Sobol H, Hardouin A, Berthet P, Peyrat JP, Fournier J, Nogues C, Lidereau R, Muller D, Fricker JP, Longy M, Toulas C, Guimbaud R, Yannoukakos D, Mazoyer S, Lynch HT, Lenoir GM, Goldgar DE, Stoppa-Lyonnet D, Sinilnikova OM.

Int J Cancer. 2005 Nov 1;117(2):230-3.

PMID:
15900600
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk